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Abstract: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by
progressive elevation of pulmonary arterial pressure and vascular resistance due to pulmonary
vasoconstriction and vessel remodeling as well as inflammation. Rho-kinases (ROCKs) are one
of the best-described effectors of the small G-protein RhoA, and ROCKs are involved in a variety
of cellular functions including muscle cell contraction, proliferation and vascular inflammation
through inhibition of myosin light chain phosphatase and activation of downstream mediators.
A plethora of evidence in animal models suggests that heightened RhoA/ROCK signaling is
important in the pathogenesis of pulmonary hypertension by causing enhanced constriction
and remodeling of the pulmonary vasculature. Both animal and clinical studies suggest that
ROCK inhibitors are effective for treatment of severe PAH with minimal risk, which supports
the premise that ROCKs are important therapeutic targets in pulmonary hypertension and that
ROCK inhibitors are a promising new class of drugs for this devastating disease.
Keywords: pulmonary arterial hypertension, Rho-kinase, vasoconstriction, fasudil

Pulmonary hypertension
Pulmonary arterial hypertension (PAH), characterized by an elevated, sustained
increase in pulmonary artery pressure greater than 25 mmHg at rest or 30 mmHg upon
exertion, is a progressive disease with poor prognosis and death usually occurring
within 5 years if left untreated.1 Further, primary or idiopathic pulmonary hypertension
(IPAH) can result in death within a median of 3 years from right ventricular failure
without treatment, with a 15% 1-year mortality rate despite current therapy.2 Factors
contributing to PAH include prolonged vasoconstriction, vascular remodeling, inflammatory cell migration, and in situ thrombosis which result in the formation of vascular
lesions.3,4 It is currently thought that the primary cause of the elevated pulmonary
vascular resistance that occurs in PAH is due to mechanical obstruction from vascular
remodeling.5,6 In addition, pathologic findings show that PAH is associated with intimal
and/or medial hypertrophy, intimal fibrosis, and plexiform lesions.7
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Although the long-term prognosis for patients with PAH is rather poor, recent advances
in the understanding of pathophysiological mechanisms underlying the progression of
PAH have been made possible through the use of experimental animal models. The
monocrotaline model of PAH, initially used over 40 years ago, is induced via a single
injection of 60 mg/kg monocrotaline either intraperitoneally or subcutaneously.8 Rapid
and severe pulmonary vascular disease usually occurs within a few days (independent of
Vascular Health and Risk Management 2009:5 663–671
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any cardiac or lung parenchymal disorders), suggesting that
this model is an excellent choice to study IPAH. Although the
basic underlying mechanism of monocrotaline-induced PAH
is not well understood, it is known that the parent compound
is not toxic, and must be activated to the reactive monocrotaline pyrrole by hepatic cytochrome P450 3A, which targets
the pulmonary vascular endothelium.9–12 A limitation of this
experimental model is that differences exist in monocrotaline
sensitivity between rat strains as well as individual variances
in the pharmacokinetics of monocrotaline involving degradation and hepatic formation of the pyrrole or conjugation
and excretion.13
A second widely employed model of PAH is the use of
chronic hypoxia. Studies show that decreasing the alveolar
oxygen pressure to 70 mmHg elicits a strong pulmonary
vasoconstrictor response; however, the hypoxic-induced
effect varies among animal species.14 For example, rabbits
show very little response to alveolar hypoxia, but cattle
exhibit the greatest vasoconstriction, and hypoxic pulmonary
vasoconstriction is milder in humans than in rats.15 Further,
the hypoxic pulmonary vasoconstrictor response varies
among humans.16 The time of exposure to hypoxia appears
to be critical as short exposure causes acute pulmonary
vasoconstriction, while prolonged hypoxia results in remodeling of the distal pulmonary arterial branches. It has also
been observed that endothelial and smooth muscle hyperplasia occurs in the walls of pulmonary arteries in rats during
the first days of hypoxic exposure.17,18 In animal models,
intermittent severe hypoxia leads to the development of
PAH, independent of the duration of the hypoxia to normoxia
intervals. However, in humans, intermittent hypoxia elicits
only a small clinically irrelevant effect on pulmonary
hemodynamics.19 Thus, caution must be exercised when
extrapolating animal models of chronic hypoxic-induced
PAH to the human setting. Another documented animal
model of PAH involves the formation of chronic emboli in
pulmonary vessels. Shelub et al induced chronic embolic
PAH through repeated microembolizations with the injection
of Sephadex® microspheres.20 The utilization of this approach
allows different-sized vessels to be targeted depending on
the diameter size of the microspheres that are injected, and
vascular obstruction and vasoconstriction are the primary
mechanisms of the high pulmonary vascular resistance that
occurs.20,21 More recently, repeated embolizations with polydextran microspheres were used in pigs to elicit a sustained
elevation in pulmonary arterial pressure.22
A recent rat animal model of experimental PAH described
by Taraseviciene-Stewart and colleagues involves the
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combination of vascular endothelial growth factor receptor
blockade with SUGEN (SU) 5416 and chronic hypoxia
exposure.23 A severe, progressive PAH occurs which is
accompanied by precapillary arterial occlusion by proliferating factor VIII-positive endothelial cells. In addition, the PAH
in these animals is resistant to treatment with drugs that are
commonly used to treat human PAH.24 Thus, it appears that
this particular model of PAH more closely mimics human
severe PAH than the monocrotaline and chronic hypoxia
models of PAH which can be successfully treated with a
variety of agents.25 Finally, the newest animal models of PAH
involve the use of genetically modified animals as genetic
screening has identified a number of potentially important
gene variants that may contribute towards the development
of PAH. For example, since a heterozygous mutation of the
BMPR2 gene which encodes for the bone morphogenetic
protein receptor-II is present in a large portion of patients
with IPAH, heterozygous BMPR2-deficient mice have been
used to mimic the human condition with limited success.26–28
Further, serotonin (5-HT), and its plasma membrane transporter (5-TTT) has been reported to be involved in the pathogenesis of PAH in humans, and genetically engineered mice
lacking the 5-HTTT exhibit attenuated hypoxia-induced PAH,
and mice overexpressing 5-HTTT can cause PAH.29,30

Current therapies for pulmonary
hypertension
Although there is a variety of drugs that are currently used or
under investigation for the treatment of PAH, there is no specific drug class that is completely efficacious in reversing the
deleterious effects of this disease. Nitric oxide (NO) has been
used with mixed success as a therapy for PAH. Exogenous
administration of the inhaled preparation of NO reduces
pulmonary vascular resistance without having an effect on
systemic vascular resistance or cardiac function.31,32 Inhaled
NO has been used to treat primary pulmonary hypertension,
secondary pulmonary hypertension in association with
congenital or acquired heart disease, chronic obstructive
pulmonary disease (COPD), and Adult Respiratory Distress
Syndrome (ARDS).33–35 Evidence suggests that the efficacy of
NO is dependent on the inhaled concentration. For example,
it has been observed that 40 ppm inhaled NO will reverse
hypoxic pulmonary vasoconstriction in healthy individuals
independent of systemic effects, and initial results showed
improvement in ARDS patients.36,37 However, it was also
reported that inhaled NO in doses greater than 10 ppm worsen
arterial oxygenation and therefore, it was suggested that
lower doses be used to treat ARDS.38 The primary limiting
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factor in the global use of inhaled NO is the potential toxicity
that may occur if high concentrations are used. Chemical
reactions with oxygen and reactive oxygen species yield
toxic nitrogen oxides and hydroxyl radicals. Subsequently,
nitrogen oxide reacts with superoxide to form peroxynitrite,
which can elicit pulmonary cellular injury.39
The prostanoids are another class of agents used to treat
PAH as these substances have been successfully tested in
animal models of PAH, and prostacyclin and its analogs
have been extensively studied in the treatment of human
PAH.40,41 Mechanistically, prostacyclin exerts vasoprotective effects through pulmonary vasodilatation, inhibition of
platelet aggregation, and pulmonary arterial smooth muscle
proliferation.42 Because of prostacyclin’s short half-life,
several analogs have been developed which appear to exhibit
long-term beneficial vasodilatory and antithrombotic effects
in patients with PAH when given by daily inhalation.43
Specifically, aerosolized iloprost causes selective pulmonary
vasodilation in patients with either primary or secondary
pulmonary hypertension.43 In contrast, beraprost has limited
effectiveness in treating both primary and secondary PAH.44,45
Most recently, it was found that intravenous epoprostenol
improves survival in patients with PAH.46
Endothelin (ET) receptor antagonists represent some of
the newest class of agents available for treatment of PAH.
The selective ETA receptor antagonist BQ-123 was the first
ET receptor antagonist to exhibit beneficial effects in animal
models of PAH, and bosentan, an antagonist of both ETA
and ETB receptors reduces the medial thickening and neomuscularization of pulmonary arteries as well as lowering
pulmonary arterial pressure in rat animal models of PAH.47–49
Studies also show that bosentan is clinically effective in
patients with PAH, which included significant improvement in exercise capacity, functional class, and pulmonary
hemodynamics.50,51
The newest and most potentially efficacious therapeutic
agents to date are the phosphodiesterase (PDE) 5 inhibitors,
which were discovered incidentally to have pulmonary
vasodilating effects in addition to being used to treat erectile dysfunction. Sildenafil attenuates the acute pulmonary
vasoconstrictor response to hypoxia in humans as well as
lowering high-altitude-induced temporary PAH in healthy
volunteers.52,53 In addition, sildenafil decreases RV mass in
patients with PAH, suggesting that PDE5 inhibitors may
be able to reverse the RV remodeling that occurs in PAH.54
Further, the combination of sildenafil and besaprost may be
efficacious in treating PAH.55 Other therapies include adrenomedullin, an endogenously produced vasodilator originally
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discovered in human pheochromocytoma, and levosimendan,
a dual calcium-sensitizing positive inotropic agent and potassium channel activator. Inhaled adrenomedullin may improve
exercise capacity and selectively decrease pulmonary vascular pressure in patients with primary pulmonary hypertension,
and intravenous levosimendan significantly lowers pulmonary vascular resistance after heart transplant procedure.56,57
Finally, calcium channel blockers have been used with
limited success as less than 10% of patients with PAH have
a beneficial acute pulmonary vasodilatory response to longterm treatment.58 Mechanisms by which currently used drugs
elicit pulmonary vasodilatation for treatment of pulmonary
hypertension are shown in Figure 1, although the limited
success of these current therapeutic regimens has been the
impetus for investigating the feasibility of therapeutically
targeting Rho-kinase signaling mechanisms in PAH.

Rho-kinase
There is convincing evidence that Rho-kinases are involved
in a variety of cardiovascular diseases including pulmonary
hypertension.59–64 Approximately seventeen years ago it was
revealed that a small monomeric GTPase called Rho induced
the formation of stress fibers and focal adhesions in 3T3
cells.65 Subsequently, a number of laboratories demonstrated
that Rho was expressed in smooth muscle and could be activated by a plethora of contractile agonists.66 Although Rho
was shown to increase Ca2+ sensitivity and phosphorylate
myosin light chain in intact smooth muscle, these events
could not occur in permeabilized smooth muscle cells, suggesting that activation required interaction of Rho with a
second component of the plasma membrane.67,68
In the mid 1990s a number of investigators working
independently identified one of the effectors of Rho and
termed it Rho-kinase, and it was postulated that this was the
component necessary for Rho activation.69,70 In 1996, it was
reported that Rho-kinase (ROCK) was activated by Rho,
which subsequently phosphorylated and inhibited myosin
light chain phosphatase.71 One year later it was found that
translocation of Rho to the plasma membrane was necessary for increasing Ca2+ sensitivity.72 Further, it was widely
documented that Rho and/or ROCK antagonists inhibited
the effect of contractile agonists indicating that both Rho
and ROCK were major effectors of agonist-induced Ca2+
sensitization in smooth muscle.67,73–75 ROCKs are serine/
threonine kinases with a molecular mass of approximately
160 kDa.1,61 These kinases are expressed in invertebrates such
as Caenorhabditis elegans, Drosophila, and mosquito, and
in vertebrates such as zebrafish, Xenopus, chicken, mouse,
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Figure 1 Mechanisms through which current drugs elicit pulmonary vasodilatation to treat pulmonary hypertension.
Abbreviations: ET-1, endothelin-1; CCBs, calcium channel blockers; PGI2, prostacyclin; NO, nitric oxide; CaM, calmodulin; SR, sarcoplasmic reticulum; AC, adenylate cyclase;
MLCK, myosin light chain kinase; MLCPh, myosin light chain phosphatase, PDE5, phosphodiesterase 5; PLC, phospholipase C; sGC, soluble guanylate cyclase.

rat, and human.61 ROCK’s catalytic site is adjacent to its
NH2 terminus, whereas the Rho binding site is located at the
COOH-terminal portion of its coiled-coil domain.66 ROCKs
regulate a variety of cellular functions including motility,
proliferation, apoptosis, contraction, and gene expression,
and are believed to be the most important regulators of
Ca2+ sensitivity in smooth muscle.61,66,76,77 ROCK-mediated
pathophysiological mechanisms that may contribute to the
development of pulmonary hypertension are summarized
in Figure 2.
Currently, two isoforms (ROCK-1 and ROCK-2) have
been identified, which are expressed in vascular smooth
muscle.61 ROCK activation increases the Ca2+ sensitivity
of contraction in vascular smooth muscle via inhibition
of myosin light chain phosphatase, which increases the
phosphorylation of myosin light chain and augments
contraction at any given level of cytosolic Ca2+ and activity
of myosin light chain kinase.78 ROCK inhibits myosin
light chain phosphatase by phosphorylating the 130 kDa
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myosin-binding subunit myosin light chain phosphatase
(MYPT-1) and/or the myosin light chain phosphatase
inhibitor protein CPI-17.66 Further, ROCKs target other
substrates that are important for smooth muscle contraction
such as calponin.61
RhoA activates ROCK after extracellular G-protein
coupled receptor binding. 72 Depending on the agonist
stimulation, ROCK may increase Ca2+ sensitivity of the
contractile apparatus via phosphorylation of MYPT-1 at
threonine (Thr)-696 and Thr-853, and phosphorylation of
CPI-17 at Thr-38.66 More recently, it was shown that ROCK
also phosphorylates Thr-855 on MYPT-1.79,80

Rho-kinases as targets
for pulmonary hypertension
Evidence strongly suggests that RhoA/ROCK is an attractive
target for the development of therapeutics to treat PAH as
many studies have shown that ROCK signaling is involved in
the sustained vasoconstriction and vascular remodeling and

Vascular Health and Risk Management 2009:5

Dovepress

Rho-kinases in pulmonary arterial hypertension

Multiple targets of Rho-kinase in pulmonary arteries
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Figure 2 Schematic illustration of possible Rho-kinase mediated pathophysiological mechanisms that may contribute to the development of pulmonary hypertension.
Abbreviation: VSMC, vascular smooth muscle cells.

inflammation that occurs in this disease. Oka et al reported
that ROCK signaling mediated vasoconstriction in severe
occlusive pulmonary hypertension in rats, and other studies
have shown that ROCKs are involved in hypoxic pulmonary
vasoconstriction, hypoxic pulmonary hypertension, and
monocrotaline-induced pulmonary hypertension.3,81–83 More
recently, studies confirmed that ROCK-mediated prolonged
vasoconstriction was inherently involved in chronic hypoxic
pulmonary hypertension in both neonatal and adult rats as
well as in bleomycin-induced pulmonary hypertension.84,85
Endothelin-1 increases pulmonary vasoconstriction via
ROCK signaling, and small pulmonary arteries exhibit
ROCK-dependent increases in myogenic tone in chronic
hypoxic pulmonary hypertension.86–88 Further, ROCKs have
been implicated in the vascular remodeling associated with
experimental models of PAH, and a recent report by Guilluy
and colleagues suggests that transglutaminase-mediated
activation of RhoA by serotonin may be involved in
pulmonary vascular remodeling induced by chronic
hypoxia.78,89–91 In humans, preliminary studies show that the
pulmonary vasodilatory response in hypertensive pulmonary
arteries and isolated perfused lung lobes removed from lung
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transplantation patients for severe PAH is associated with
high RhoA/ROCK activity.92
Studies involving ROCK inhibitors have been primarily
done with either fasudil or Y-27632. Both compounds are
cell-permeable and potently inhibit ROCK in vascular
smooth muscle. 93,94 Fasudil, initially described as an
intracellular calcium antagonist, is a selective inhibitor of
ROCK.61,74,95 Specifically, fasudil is metabolized in the liver
to the active compound hydroxyfasudil, which is a specific
ROCK inhibitor because its efficacy for ROCK is 100-fold
higher than for protein kinase C (PKC), and 1000-fold higher
than for myosin light chain kinase.93,96 Similarly, Y-27632,
a pyridine derivative, binds to and inhibits p160ROCK up
to 200-fold higher than PKC or PKA.74
The mechanisms by which ROCK antagonists attenuate
PAH are widespread. Evidence from in vivo studies suggests
that the effect of ROCK inhibitors is associated with
decreased pulmonary artery expression of growth factors and
markers of cell proliferation, matrix protein production, and
inflammatory cell infiltration as well as an increase in signals
for apoptosis.97 In vitro studies also suggest a negating effect
of ROCK inhibitors on pulmonary vascular cell growth.
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Chapados and colleagues reported that Y-27632 prevented
stress fiber formation and reduced nuclear extracellular
signal-regulated kinase and tenascin-C expression. 98
In animal models of PAH, fasudil or Y-27632 decreases the
sustained vasoconstrictor response and vascular remodeling
that occurs during exposure to monocrotaline or hypoxia.78,99
Further, inhibition of ROCK attenuates pulmonary arterial
pressure and reverses pulmonary vasoconstriction caused by
NO synthase (NOS) antagonists in chronically hypoxic lungs,
and ROCK antagonists also lower acute hypoxia-mediated
contraction of isolated rat pulmonary artery segments and
isolated mouse lungs.77,78,83 Oka et al also showed that this
same compound acutely lowered right ventricular systolic
pressure in SU5416/hypoxia-exposed rat lungs.3 In mouse
models of PAH, treatment with Y-27632 decreased the
muscularization of distal pulmonary arteries and upregulated
eNOS expression, and Abe and colleagues observed that
inhibiting chronic hypoxic PAH in mice increased lung eNOS
expression and Akt phosphorylation.78,100
Finally, evidence suggests that statins may also be
effective inhibitors of ROCK. Statins (HMG-CoA reductase
inhibitors) block the synthesis of mevalonate and its
isoprenoid intermediate compound geranylgeranylpyrophosphate, which subsequently inhibits isoprenylation of RhoA
and its translocation to the plasma membrane.101 Statins ameliorate PAH in a variety of rat models, and a recent report by
Girgis et al provides evidence that reversal of hypoxic PAH
by simvastatin is coupled to decreased lung expression and
activity of both ROCK I and II.24,102–107 In addition, Li et al
observed that atorvastatin blocked serotonergic-mediated
pulmonary artery smooth muscle proliferation and migration
by inhibiting membrane translocation of RhoA.108

Rho-kinase inhibitors as therapies
for pulmonary hypertension
ROCK inhibitors have been used for approximately 15 years
to treat cardiovascular disorders including vasospasm after
subarachnoid hemorrhage and stable effort angina pectoris
with no adverse effects.61,95 Although relatively few, clinical
studies with ROCK inhibitors also show that fasudil is an
effective treatment for severe pulmonary hypertension.
In PAH patients that did not respond to oxygen inhalation,
NO inhalation, or nifedipine, 30-minute intravenous fasudil
treatment significantly decreased elevated pulmonary
vascular resistance without causing systemic hypotension.63
Further, Ishikura et al confirmed that fasudil had acute beneficial pulmonary hemodynamic effects in patients with PAH.109
Collectively, these clinical studies suggest that ROCK
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signaling is a viable therapeutic target as a treatment for
pulmonary hypertension with ROCK inhibitors (Figure 1).
However, although fasudil appears to be a promising agent
to use for PAH, long-term effects of fasudil administration
in patients with severe pulmonary hypertension need to be
evaluated before more definitive conclusions can be made as
to the efficacy of this type of agent. Studies also suggest that
this drug can be used for other cardiovascular diseases with
minimal side effects. Oral treatment with fasudil for at least
4 weeks significantly lengthened maximum exercise time
without any effect on blood pressure and heart rate during
the exercise independent of any serious unwanted side effects
from the drug.61 In addition, fasudil improved myocardial
ischemia in patients with microvascular angina caused by
coronary microvascular vasoconstriction.110

Conclusions
One of the biggest obstacles in treating pulmonary
hypertension is identifying effective therapeutic agents that
selectively target the pulmonary vasculature with minimal
side effects. The RhoA/ROCK signaling pathway is an
important regulator of pulmonary vascular function and
animal studies have shown that this pathway is important in
the pathogenesis of major disease states such as pulmonary
hypertension. Further studies should be done to determine
how ROCKs mediate pulmonary vascular smooth muscle
cell physiology and how these moieties are involved in
vascular disease states. Recent clinical studies in humans
show promise in that acute treatment with ROCK inhibitors
in patients with severe pulmonary hypertension exhibited
signs of improved pulmonary vascular function by attenuating the ROCK-mediated increase in pulmonary vascular
resistance. Towards this end, large clinical trials are the
logical next step in demonstrating that long-term treatment
with ROCK inhibitors is both safe and efficacious in patients
with pulmonary hypertension.
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